Regulatory Schema for Blood Transfusion Microbiotal transplant conference

Size: px
Start display at page:

Download "Regulatory Schema for Blood Transfusion Microbiotal transplant conference"

Transcription

1 Regulatory Schema for Blood Transfusion Microbiotal transplant conference Baltimore, 3-4 December 2015 John R. Hess, MD, MPH, FACP, FAAAS Professor of Laboratory Medicine Medical Director, Transfusion Service Harborview Medical Center U. of Washington School of Medicine, Seattle Special Advisor to Director General, Blood Safety, 2003 WHO Expert Panel, Blood Transfusion Medicine,

2 The safest blood is Collected from the safest members of the population Tested for infectious diseases of risk Stored and transported in a safe manner Given to the right patient For the right reason WHO Global Program for Blood Safety

3 Biologics Control Act of 1902 Followed St. Louis disaster (diphtheria antitoxin contaminated with tetanus killed 13 children) Pre-market approval (license) to manufacture a product to be shipped in interstate commerce Registration of a manufacturer Naming of a responsible head (authorized official)

4 Pure Food and Drug Act of 1906 Progressive era, Sinclair Louis & The Jungle For preventing the manufacture, sale, or transportation of adulterated or misbranded or poisonous or deleterious foods, drugs, medicines, and liquors,. Purity and potency required (but not safety or efficacy). False claims illegal, but anything in the US Formulary or US Pharmacopea was legal if correctly labeled. Subsequent deaths from dinitrophenol, cincophen, radium, iodine, etc.

5 Food, Drug, and Cosmetics Act of 1938 Followed Elixor of Sulfanilamide disaster (sulfa in diethylene glycol labeled as elixor killed >100 people) Drugs sold in interstate commerce must be safe. Blood for transfusion is a drug. Authority with FDA

6 Drug Amendments of 1962 Followed thalidomide disaster in Germany and England (phocomelia in infants) Drugs must be safe and effective.

7 Where are we? Blood is a drug Unit of manufacture is the single donation Must be safe and effective, but that cannot be measured on every unit prospectively So we enforce purity and potency

8 The regulatory divide Blood Well understood process and highly reproducible product Minimal manipulation of the product Human cells and tissues Poorly understood processes. Highly variable products Highly manipulated product

9 Source Plasma Collection Commercial plasma collection centers using paid donors for manufactured plasma products Albumin, IVIg, RhoGam, RabiesIg, Vig All of these products undergo 4-10 log of pathogen reduction by Solvent/detergent treatment Nanofiltration Other methods

10 The safest blood comes from altruistic voluntary nonremunerated donors. WHO Global Program for Blood Safety

11 Give Blood The national blood policy established in the late 1970s requires that blood for transfusion be donated by voluntary donors. It s not a monumental effort

12 Making a blood product Define a product (like a unit of RBCs) Describe a process to make it Prove it works (under an IND) Get a license to make the product by following procedures that define the process.

13 Modern integral blood bag system

14 Making Blood Products Recruiting donors Qualifying donors Collecting whole blood Testing blood collected Making components Labeling Storage Shipment

15 Donor Suitability Blood components for transfusion Serum eye drops Plasma for fractionation Human milk Human sperm or ova Human fecal microbiota Human vaginal microbiota Human oral microbiota

16 21 CFR Suitability of donor (a) Method of determining. The suitability of a donor as a source of Whole Blood shall be determined by a qualified physician or by persons under his supervision and trained in determining suitability. a thru f: (covering or referencing just about everything)

17 cgmp Current good manufacturing practice, the model is ISO-9001 Have a quality program Have written procedures for each process Measure deviation from the process Perform root-cause evaluations into sources of deviations Minimize deviation from the process by enforcing or changing procedure

18 Blood Safety in US is a matter of FDA regulation and industry standards FDA regulations in 21 CFR 200, 600, 800, & 1270 series, 42 CFR 493w Blood collection and product manufacturing facilities are licensed and distributing facilities are registered. FDA inspections biannually Hospitals, laboratories, and blood banks are accredited by TJC, CAP, and AABB State health department license

19 CFR Title 21- Food & Drugs Chapter 1 FDA in DHHS Subchapter C Drugs: general Part 210 cgmp in manufacture, processing, packing or holding of drugs: general Sect Status of cgmp regulations Sec 210.1(b) The failure to comply with any regulation set forth in this part and in parts 211, 225, and 226 of this chapter in the manufacture, processing, packing or holding of a drug shall render such a drug to be adulterated...

20 21 CFR Quality Regulations QC/QA Personnel qualifications Personnel responsibilities Production records review Laboratory records & review Personnel Facilities Equipment Supplies, reagents SOPs Records Adverse reactions BPDs

21 21 CFR Dating periods for licensed biological products The minimum dating periods in paragraph (c) of this section are based on data related to usage, clinical experience, or laboratory tests that establish the reasonable period beyond which the product cannot be expected to yield its specific results and retain its safety, purity, and potency, provided the product is maintained at the recommended temperatures

22 Labeling Labeling of a blood product is highly regulated and all such products in the US use a schema called ISBT 128. Label can only be applied when all conditions are met.

23 Labeling Human fecal slurry for microbiotal transplant Brand name Source & address FDA Registration # Unique ID # Outdate Volume Storage instructions Reference to use instructions For administration only under the direction of a licensed physician

24 Apheresis Platelet Components Single donor platelets by apheresis must contain > 3 x per unit, but some donors can give > 600 or 900 billion at a setting, enough for 2 or 3 doses. Huge advantage because of cost of collection and testing is spread over more units single donor platelets by apheresis

25 Size of donation matters because the cost of testing is spread over the number of products produced from each donation.

26 21 CFR Testing the blood All laboratory tests shall be made on a specimen of blood taken from the donor at the time of collecting the unit of blood, and these tests shall include the following: a thru f: (covering or referencing just about everything)

27 42 CFR Condition: Immunohematology The speciality of immunohematology includes four subspecialties for the purposes of proficiency testing: ABO group and D (Rho) typing, unexpected antibody detection, compatibility testing, and antibody identification. Three times yearly proficiency testing with external quality standards CAP surveys

28 42 CFR Standard: ABO & RhD typing (a)failure to attain a score of at least 100 percent of acceptable responses for each analyte or test in each testing event is unsatisfactory analyte performance for the testing event. Failures are reported to your state health department, who visits you.

29 42 CFR Civil money penalty (a) Statutory basis. Sections 1846 of the Act and 353(h)(B) of the PHS Act authorize the Secretary to impose civil money penalties on laboratories. Section 1846(b)(3) of the Act specifically provides thea incrementally more severe fines may be imposed for repeated or incorrected deficiencies.

30 Washington Post, 9 Sept 2006 Regulation is designed to ensure that blood collection and product manufacturing are in compliance with laws and regulations.

31 Increased personal choice and market forces in blood collection and donation may not be useful answers.

32

33

34

35 Fecal donor for microbial tranplant guidelines suggested by the Infectious Disease Society and 4 US GI Societies in 2013

36 Welcome to AdvancingBio: offering treatment to those suffering with C. diff through Fecal Microbiotal Transplant See website of AdvancingBio Subsidiary of BloodSource, the Sacramento area blood collector

37 Thank you for all your efforts to encourage blood donation.

Holly Rapp, MT(ASCP)SBB, CQA(ASQ)CQM/OE AABB

Holly Rapp, MT(ASCP)SBB, CQA(ASQ)CQM/OE AABB Holly Rapp, MT(ASCP)SBB, CQA(ASQ)CQM/OE Director, Accreditation and Quality AABB The Beginning of Biologics Regulation Vaccines used to prevent smallpox and rabies at the end of the 19 th century Heat

More information

FDA Perspective on Plasma Quality and GMPs

FDA Perspective on Plasma Quality and GMPs FDA Perspective on Plasma Quality and GMPs Judy Ellen Ciaraldi Food and Drug Administration Division of Blood Components & Devices/OBRR/CBER IPFA/BCA Global Symposium September 23, 2014 Sacramento, California

More information

Sharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY. June 7, 2016

Sharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY. June 7, 2016 Sharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY June 7, 2016 1 Brief description of the Mount Sinai Cellular Therapy Laboratory Overview of BM transplant

More information

Over the last 20 to 30 years, there has been a big cultural change in blood establishments: Scientific focus (Testing)

Over the last 20 to 30 years, there has been a big cultural change in blood establishments: Scientific focus (Testing) Over the last 20 to 30 years, there has been a big cultural change in blood establishments: Scientific focus (Testing) Therapeutic focus (Manufacturing) Quality & Regulatory Consultant 2 This change has

More information

Error Management and BPD Reporting for the Transfusion Service. Mary A Lieb MT(ASCP)SBB, CQA(ASQ) Director, Quality Source Blood Systems,

Error Management and BPD Reporting for the Transfusion Service. Mary A Lieb MT(ASCP)SBB, CQA(ASQ) Director, Quality Source Blood Systems, Error Management and BPD Reporting for the Transfusion Service Mary A Lieb MT(ASCP)SBB, CQA(ASQ) Director, Quality Source Blood Systems, Objectives Define biological product deviation Explain what constitutes

More information

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics

More information

Reporting Deviations of Biological Products and HCT/Ps. Ellen Areman Senior Consultant Biologics Consulting Group, Inc.

Reporting Deviations of Biological Products and HCT/Ps. Ellen Areman Senior Consultant Biologics Consulting Group, Inc. Reporting Deviations of Biological Products and HCT/Ps Ellen Areman Senior Consultant Biologics Consulting Group, Inc. Relevant Legislation Public Health Service (PHS) Act Regulates biological products

More information

EXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER

EXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER EXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER Disclaimer: This example is just one potential example of a vendor qualification form to verify the adequacy of the internal

More information

US FDA: CMC Issues for INDs

US FDA: CMC Issues for INDs ISBTC Global Regulatory Summit October 29, 2008 US FDA: CMC Issues for INDs Keith Wonnacott, Ph.D. keith.wonnacott@fda.hhs.gov US Food and Drug Administration Center for Biologics Evaluation and Research

More information

History of cgmp s & FDA. Richard Lombardi, Training Specialist Forest Laboratories, Inc.

History of cgmp s & FDA. Richard Lombardi, Training Specialist Forest Laboratories, Inc. History of cgmp s & FDA Richard Lombardi, Training Specialist Forest Laboratories, Inc. ASQ June 1, 2005 Not a second thought What Ails Ya? Latham's Cathartic Extract: : Sick, headache, Impurities in the

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics Additional copies of this guidance are available from the Office of Communication, Training and Manufacturers Assistance

More information

Draft Guidance for Industry. This guidance document is for comment purposes only.

Draft Guidance for Industry. This guidance document is for comment purposes only. Reprinted from FDA s website by EAS Consulting Group, LLC Bacterial Detection Testing by Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations 1 of 6 6/10/2009 10:36 AM Inspections, Compliance, Enforcement, and Criminal Investigations hhsbluebirddepartment of Health and Human Services Public Health Service Food and Drug Administration Dallas

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information

CGMP Requirements for Investigational Products

CGMP Requirements for Investigational Products PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health

More information

Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture

Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture Reprinted from FDA s website by EAS Consulting Group, LLC Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture Guidance

More information

Common AABB Assessment Findings

Common AABB Assessment Findings Common AABB Assessment Findings Linda Sigg, MT(ASCP)SBB, CQA(ASQ) Staff Lead Assessor, Accreditation and Quality AABB Southeastern Area Blood Bankers Association Annual Meeting March 4-5, 2009 Introduction

More information

The Quality Conundrum

The Quality Conundrum The Quality Conundrum High Resource TM Standards in Low Resource Environments Alexander Duncan MD Centre for Transfusion & Cellular Therapies Emory University School of Medicine Case 1 29 yr old woman

More information

Compliance Program Guidance Manual Chapter 42 Blood and Blood Products

Compliance Program Guidance Manual Chapter 42 Blood and Blood Products Compliance Program Guidance Manual Chapter 42 Blood and Blood Products Inspection of Licensed In-Vitro Diagnostic (IVD) Devices Regulated by CBER - 7342.008 Implementation Date: October 1, 2012 PRODUCT

More information

Quality Management. Carlos Bachier, MD

Quality Management. Carlos Bachier, MD Quality Management Carlos Bachier, MD Goals of Quality Management Ensure credibility of outcomes Improve patient safety and quality of processes Significantly reduce errors Quality Medical and Laboratory

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Puget Sound Blood

More information

Pathogen Inactivation and Blood Safety in the US. Richard Benjamin, MD PhD Chief Medical Officer Washington, D.C.

Pathogen Inactivation and Blood Safety in the US. Richard Benjamin, MD PhD Chief Medical Officer Washington, D.C. Pathogen Inactivation and Blood Safety in the US Richard Benjamin, MD PhD Chief Medical Officer Washington, D.C. Conflict of Interest The American Red Cross is participating in a clinical trial of the

More information

CGMP for Phase 1 INDs

CGMP for Phase 1 INDs CGMP for Phase 1 INDs Laurie P. Norwood Deputy Director Division of Manufacturing and Product Quality Office of Compliance and Biologics Quality Center for Biologics Evaluation and Research 1 Overview

More information

FDA Update on Compounding

FDA Update on Compounding FDA Update on Compounding Julie Dohm, JD, PhD Senior Science Advisor for Compounding, Center for Drug Evaluation and Research; Agency Lead on Compounding, FDA Compounding A Snapshot Compounded drugs: Are

More information

SECTION L QUALITY ASSURANCE. 1) designating and managing quality control functions, including:

SECTION L QUALITY ASSURANCE. 1) designating and managing quality control functions, including: NT-L1.000 QUALITY ASSURANCE PROGRAM All NADOs shall have a QA Program. Current (2 nd Edition) NT-L1.100 BASIC ELEMENTS SECTION L QUALITY ASSURANCE The QA program shall include, at a minimum: 1) designating

More information

Regulatory Approval of Modern Gene-Based Cancer Immunotherapies CAR T Cells A product perspective

Regulatory Approval of Modern Gene-Based Cancer Immunotherapies CAR T Cells A product perspective Regulatory Approval of Modern Gene-Based Cancer Immunotherapies CAR T Cells A product perspective ASQ509 Biomed/Biotech SIG 2/1/18 Xiaobin Victor Lu Division of Cellular and Gene Therapies Office of Tissues

More information

Office for Human Subject Protection. University of Rochester

Office for Human Subject Protection. University of Rochester POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,

More information

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 Clinical Trials and the Code of Federal Regulations Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 The Development of Regulations 1906: Food and Drugs Act

More information

EU and FDA GMP Regulations: Overview and Comparison

EU and FDA GMP Regulations: Overview and Comparison THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational

More information

Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act

Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance U.S. Department of Health and Human Services Food and Drug Administration Center for

More information

Challenges In Cell Product Labeling, Tracking And Traceability

Challenges In Cell Product Labeling, Tracking And Traceability Challenges In Cell Product Labeling, Tracking And Traceability April 4-5, 2008 Columbus, Ohio Dave Krugh, MT(ASCP)SBB, CLS,CLCP(NCA) Clinical Program Manager, BMT Program Clinical Instructor, Department

More information

Regulation of Biologics in The United States: From a Rich Tradition To A Challenging Future

Regulation of Biologics in The United States: From a Rich Tradition To A Challenging Future Regulation of Biologics in The United States: From a Rich Tradition To A Challenging Future Chris Joneckis,, Ph.D. Senior Advisor For CMC Issues Center For Biologics Evaluation And Research Food and Drug

More information

HCT/P Regulation vs 361 Products

HCT/P Regulation vs 361 Products HCT/P Regulation - 351 vs 361 Products Presented by: Paul Gadiock February 15, 2017 Arent Fox LLP Washington, DC New York, NY Los Angeles, CA San Francisco, CA 1 Presentation Overview Introduction Public

More information

6TH EDITION OF FACT-JACIE STANDARDS A QUICK SUMMARY. BHS JACIE Day, 6 March 2015 Eoin McGrath JACIE Operations Manager

6TH EDITION OF FACT-JACIE STANDARDS A QUICK SUMMARY. BHS JACIE Day, 6 March 2015 Eoin McGrath JACIE Operations Manager 6TH EDITION OF FACT-JACIE STANDARDS A QUICK SUMMARY BHS JACIE Day, 6 March 2015 Eoin McGrath JACIE Operations Manager CONTENTS Review process Sources of information Selection of main changes and developments

More information

License Submission Checklist for Platelets, Leukocytes Reduced Collected by Pheresis

License Submission Checklist for Platelets, Leukocytes Reduced Collected by Pheresis License Submission Checklist for Platelets, Leukocytes Reduced Collected by Pheresis Purpose: To provide guidance when submitting documentation to FDA in support of a BLA or a license supplement. Definitions

More information

ABO, Rh, HLA Antibodies Issues with Whole Blood NANCY M. DUNBAR, MD MEDICAL DIRECTOR, BLOOD BANK DARTMOUTH-HITCHCOCK MEDICAL CENTER, LEBANON, NH, USA

ABO, Rh, HLA Antibodies Issues with Whole Blood NANCY M. DUNBAR, MD MEDICAL DIRECTOR, BLOOD BANK DARTMOUTH-HITCHCOCK MEDICAL CENTER, LEBANON, NH, USA ABO, Rh, HLA Antibodies Issues with Whole Blood NANCY M. DUNBAR, MD MEDICAL DIRECTOR, BLOOD BANK DARTMOUTH-HITCHCOCK MEDICAL CENTER, LEBANON, NH, USA The Appeal of Whole Blood WHOLE BLOOD IN EXSANGUINATING

More information

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals

Quality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality

More information

Cell and Gene Therapy Medicinal Product Management Act (Draft) General Information

Cell and Gene Therapy Medicinal Product Management Act (Draft) General Information Cell and Gene Therapy Medicinal Product Management Act (Draft) General Information July 2017 At present there are still many diseases that cannot be cured by current medical technology and existing chemical

More information

Quality Program: Supplies and Reagents

Quality Program: Supplies and Reagents Quality Program: Supplies and Reagents J. Wade Atkins, MS, MT(ASCP) SBB, CQA (ASQ) Supervisor, Quality Assurance and Regulatory Affairs Department of Transfusion Medicine, Clinical Center, NIH Disclosures:

More information

March 9, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852

March 9, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org March 9, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration

More information

FDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC)

FDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC) FDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC) Ellen Lazarus, M.D. Medical Officer Division of Human Tissues Office of Cellular, Tissue, and Gene Therapies FDA proposed approach

More information

Facility and Operational Issues for Cord Blood Banks: FDA Draft Guidance

Facility and Operational Issues for Cord Blood Banks: FDA Draft Guidance Facility and Operational Issues for Cord Blood Banks: FDA Draft Guidance Mary Malarkey, Director Office of Compliance and Biologics Quality ISCT 7 th Annual Somatic Cell Therapy Symposium, September 26-28,

More information

San Jose, California, USA

San Jose, California, USA Glisland, Inc. San Jose, California, USA http://www.glisland.com Welcome to the Drug GMP World Current Good Manufacturing Practice cgmp ICH Q10 Pharmaceutical Quality System PQS GMP QSR Quality System

More information

Regula'on of Contracep'ves

Regula'on of Contracep'ves Regula'on of Contracep'ves VETERINARY DRUG DEVELOPMENT: REGULATION OF STERILANTS AND CONTRACEPTIVES David M. Petrick, VMD, JD The Delta Consortium Regulatory Consulting Limited Copyright July, 2018 Veterinary

More information

PROVINCIAL BLOOD COORDINATING PROGRAM DEFINITIONS NLBCP-063

PROVINCIAL BLOOD COORDINATING PROGRAM DEFINITIONS NLBCP-063 Government of Newfoundland and Labrador Department of Health and Community Services Provincial Blood Coordinating Program PROVINCIAL BLOOD COORDINATING PROGRAM DEFINITIONS Office of Administrative Responsibility

More information

Quality Manual. Quality Manual. Vera Bioscience / Anu Life Sciences. April 2018

Quality Manual. Quality Manual. Vera Bioscience / Anu Life Sciences. April 2018 Quality Manual Vera Bioscience / Anu Life Sciences April 2018 Page 1 of 15 TABLE OF CONTENTS Quality Manual Page 1. Company Overview 3 2. References 3 3. Exemptions, Alternatives and Variances 3 4. General

More information

FACT Common Standards for Cellular Therapies, Second Edition. Summary of Changes

FACT Common Standards for Cellular Therapies, Second Edition. Summary of Changes FACT Common Standards for Cellular Therapies, Second Edition Summary of Changes This document summarizes major changes made to the Second Edition FACT Common Standards for Cellular Therapies. This summary

More information

Introduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES

Introduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES Introduction to GMPs and Validation WILLIAM GARVEY AND ASSOCIATES William Garvey and Associates LLC 2016 Introduction About your instructor William (Bill) Garvey Important regulations and events Good Manufacturing

More information

DEPARTMENT OF HEALTH 81 HUMAN SERVICES

DEPARTMENT OF HEALTH 81 HUMAN SERVICES I. DEPARTMENT OF HEALTH 81 HUMAN SERVICES Public Health Servke Food and Drug Admlnistration I:& ;5 -. San Francisco Distinct 1431 Harbor Bay Parkway Alameda. CA 94502-7070 Telephone: 51 O/337-6700 VIA

More information

Autologous Supply Chain

Autologous Supply Chain Autologous Supply Chain INSIGHTS INTO THE REGULATORY CONSIDERATIONS FOR SHIPPING VALIDATION SUPPORTING NOVEL PRODUCTS - CELLULAR PRODUCTS 1 Federal Food, Drug, & Cosmetic Act(FDCA) Under Sec 501(a)(2)(B)

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Thomas E. Young,

More information

Human Tissue Intended for Transplantation Skin, corneas, sclera, bone, heart valves, blood vessels, pericardium, tendons, cartilage, fascia

Human Tissue Intended for Transplantation Skin, corneas, sclera, bone, heart valves, blood vessels, pericardium, tendons, cartilage, fascia TITLE / DESCRIPTION: DEPARTMENT: Human Tissue Intended for Transplantation Skin, corneas, sclera, bone, heart valves, blood vessels, pericardium, tendons, cartilage, fascia Surgical Services PERSONNEL:

More information

Stem Cell Uses and FDA Regulation

Stem Cell Uses and FDA Regulation Stem cells have been called everything from cure-alls to miracle treatments. But don t believe the hype. Some unscrupulous providers offer stem cell products that are both unapproved and unproven. So beware

More information

Re: Docket No. FDA 2018-D-2478, Recommendations for Reducing the Risk of Transfusion- Transmitted Babesiosis draft guidance, July 27, 2018

Re: Docket No. FDA 2018-D-2478, Recommendations for Reducing the Risk of Transfusion- Transmitted Babesiosis draft guidance, July 27, 2018 September 28, 2018 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA 2018-D-2478,

More information

ISBT128 Standards for Blood and Blood Components: How it Translates to Patient Safety

ISBT128 Standards for Blood and Blood Components: How it Translates to Patient Safety ISBT128 Standards for Blood and Blood Components: How it Translates to Patient Safety Diana Teo Blood Services Group Health Sciences Authority Singapore 11/12/2010 1 All Rights Reserved 2008 Health Sciences

More information

CLIA Corner. In This Issue... Common Deficiencies. Proficiency Testing Personnel Micro Quality Control

CLIA Corner. In This Issue... Common Deficiencies. Proficiency Testing Personnel Micro Quality Control CLIA Corner The University of Iowa Hygienic Laboratory First Quarter 2006 Iowa CLIA Surveyors: Nancy Grove, BS, MT(ASCP) & Kristine Rotzoll, BS, MT(ASCP) In This Issue... Common Deficiencies Proficiency

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Celltex Therapeutics Corporation

More information

Important Updates in USP <797> and USP <823> Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey

Important Updates in USP <797> and USP <823> Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey Important Updates in USP and USP Eric S. Kastango, MBA, BS Pharm, FASHP Clinical IQ, LLC & CriticalPoint, LLC Madison, New Jersey Disclosures Principal-Clinical IQ, LLC Healthcare consulting

More information

Pharmaceutical Reference Standards: Overview and Role in Global Harmonization

Pharmaceutical Reference Standards: Overview and Role in Global Harmonization Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference

More information

FDA s Same Surgical Procedure Draft Guidance Could Stifle Use of Autologous Stem Cell Therapies

FDA s Same Surgical Procedure Draft Guidance Could Stifle Use of Autologous Stem Cell Therapies FDA s Same Surgical Procedure Draft Guidance Could Stifle Use of Autologous Stem Cell Therapies Executive Summary, June 2015 Life Sciences Practice Group AUTHOR Areta L. Kupchyk Nixon Peabody LLP Washington,

More information

Impact of WHO Guidelines on GMP for Blood Establishments

Impact of WHO Guidelines on GMP for Blood Establishments Impact of WHO Guidelines on GMP for Blood Establishments Christian Schärer, Ph.D. Swissmedic, Swiss Agency for Therapeutic Products, Head Inspectorate International Conference of Drug Regulatory Authorities

More information

Disclosures. Laboratory Stakeholders. IVD vs. LDT. FDA Regulation of Laboratory Developed Tests 10/2/2015. FDA Regulation of LDTs

Disclosures. Laboratory Stakeholders. IVD vs. LDT. FDA Regulation of Laboratory Developed Tests 10/2/2015. FDA Regulation of LDTs Disclosures FDA Regulation of Laboratory Developed Tests Beaumont Health System, 24 th Annual Symposium on Molecular Pathology September 16, 2015 Roger D. Klein, MD JD Director, Molecular Pathology Clinical

More information

The Role of Research in Supporting Regulation of Biologicals: Building Bridges from Biomedical Discovery to Innovative Products

The Role of Research in Supporting Regulation of Biologicals: Building Bridges from Biomedical Discovery to Innovative Products The Role of Research in Supporting Regulation of Biologicals: Building Bridges from Biomedical Discovery to Innovative Products Jay S. Epstein, M.D. CBER, FDA Biologicals are Complex Products Critical

More information

Cell Therapy Liaison Meeting, January 27, 2006

Cell Therapy Liaison Meeting, January 27, 2006 Cell Therapy Liaison Meeting, January 27, 2006 Bethesda, MD, Summary Attendees were welcomed by Stephen J. Noga, MD, PhD, ISCT FDA Liaison and the meeting was called to order at 8:15am. HIV and HCV NAT

More information

Prepublication Requirements

Prepublication Requirements Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals

More information

SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2055

SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2055 Brief* SESSION OF 2017 SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2055 As Recommended by House Committee on Health and Human Services HB 2055 would amend the Kansas Pharmacy Act (Act) by deleting, adding, and

More information

Serological Testing: Why we did what we did!

Serological Testing: Why we did what we did! Serological Testing: Why we did what we did! W. John Judd, FIBMS, MIBiol Emeritus Professor University of Michigan What we did Provided blood and blood products in a timely, cost-efficient manner. Implemented

More information

Quality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines

Quality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:

More information

FACT Inspector Standards Review Questions 5 th Edition Cord Blood Standards

FACT Inspector Standards Review Questions 5 th Edition Cord Blood Standards FACT Inspector Standards Review Questions 5 th Edition Cord Blood Standards Inspector Name: Note: A score of 90% or higher is required to achieve active inspector status. Inspector Techniques 1. As a FACT

More information

March 4, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

March 4, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 March 4, 2014 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2013-N-1523: Request for Nominations: Drug Products that

More information

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017

Phase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/

More information

Food and Drug Administration (FDA) 101

Food and Drug Administration (FDA) 101 Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the

More information

PLATELET GUIDANCE DOCUMENT

PLATELET GUIDANCE DOCUMENT Government of Newfoundland and Labrador Department of Health and Community Services Provincial Blood Coordinating Program PLATELET GUIDANCE DOCUMENT Office of Administrative Responsibility Director, Regional

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Seite 1 von 10 Inspections, Compliance, Enforcement, and Criminal Investigations Laboratoire Atlas Inc. 6/25/09 hhsbluebird Department of Health and Human Services Public Health Service Food and Drug Administration

More information

Off-Label Use Congress and FDA must balance: The need to regulate manufacturer promotion of off-label use of devices; and The need for and availabilit

Off-Label Use Congress and FDA must balance: The need to regulate manufacturer promotion of off-label use of devices; and The need for and availabilit Off-Label Use Versus Clinical Trial Use of Devices: FDA Regulatory Issues Neil F. O Flaherty Principal Olsson Frank Weeda Terman Bode Matz PC Off-Label Use Uses that do not appear in a device s FDA-approved

More information

An overview of the Asia Pacific Blood Network and Overview of the status of plasma fractionation in the region

An overview of the Asia Pacific Blood Network and Overview of the status of plasma fractionation in the region An overview of the Asia Pacific Blood Network and Overview of the status of plasma fractionation in the region Overview» APBN Membership Vision and mission & strategic objectives Activities Plasma for

More information

Under this license, you are approved to manufacture aflibercept drug substance intermediate, drug substance, and formulated bulk at

Under this license, you are approved to manufacture aflibercept drug substance intermediate, drug substance, and formulated bulk at DEPARTMENT OF HEALTH AND HUMAN SERVICES Silver Spring MD 20993 Our STN: BL 125387/0 BLA APPROVAL November 18, 2011 Regeneron Pharmaceuticals, Inc. Attention: Laura Pologe, Ph.D. Associate Director, Regulatory

More information

NEW YORK STATE DEPARTMENT OF HEALTH CLINICAL LABORATORY EVALUATION PROGRAM. Crosswalk of Proposed Revision to General Systems Standards

NEW YORK STATE DEPARTMENT OF HEALTH CLINICAL LABORATORY EVALUATION PROGRAM. Crosswalk of Proposed Revision to General Systems Standards Any General Systems Standards not addressed here remain in effect. (changes are underlined) CURRENT STANDARD CURRENT GUIDANCE PROPOSED STANDARD PROPOSED GUIDANCE Quality Management System Sustaining Standard

More information

ORC Sponsor-Investigator IDE Checklist

ORC Sponsor-Investigator IDE Checklist A sponsor-investigator assumes BOTH investigator and sponsor responsibilities as outlined in the FDA Code of Federal Regulations 21CFR812. This means that such investigators have additional responsibilities.

More information

Inspections, Compliance, Enforcement, and Criminal Investigations

Inspections, Compliance, Enforcement, and Criminal Investigations Seite 1 von 8 Inspections, Compliance, Enforcement, and Criminal Investigations Department of Health and Human Services Public Health Service Food and Drug Administration Center for Biologics Evaluation

More information

Recent FDA Inspection Findings and Trends

Recent FDA Inspection Findings and Trends Jan-09 Feb-09 Mar-09 Apr-09 May-09 Jun-09 Jul-09 Aug-09 Sep-09 Oct-09 Nov-09 Dec-09 Jan-10 Feb-10 Mar-10 Apr-10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 Jan-11 Feb-11 Mar-11 Apr-11 May-11

More information

Irish Blood Transfusion Service Seirbhís Fuilaistriúcháin na héireann

Irish Blood Transfusion Service Seirbhís Fuilaistriúcháin na héireann Document Detail Irish Blood Transfusion Service Seirbhís Fuilaistriúcháin na héireann Type: Document No.: Title: PMF IBTS SPEC IBTS/PMF/SPEC/0201[2] PRODUCT MASTER FILE - GENERAL REQUIREMENTS Owner: 1066

More information

Regulatory Issues in Human Subjects Research

Regulatory Issues in Human Subjects Research Regulatory Issues in Human Subjects Research Ian McNiece, PhD University of Miami Human Subjects Research Require IRB approval Studies of new drugs or applications of drugs require an FDA approved IND

More information

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel

Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active

More information

PPTA Regulatory Workshop June 13, 2016

PPTA Regulatory Workshop June 13, 2016 PPTA Regulatory Workshop June 13, 2016 DOROTY SCOTT Dr. Dorothy Scott is the Branch Chief for the Laboratory of Plasma Derivatives, in the Office of Blood Research and Review, CBER. Her group is responsible

More information

Synopsis: FDA Process Validation Guidance

Synopsis: FDA Process Validation Guidance Synopsis: FDA Process Validation Guidance This synopsis is a comparison of the draft version 2008 and the final version 2011 of the U.S. FDA Guidance Process Validation: General Principles and Practices.

More information

Good manufacturing practices

Good manufacturing practices ORIGINAL PAPER 1AR-10 ISBT Science Series (2009) 4, 6 10 Journal compilation 2009 International Society of Blood Transfusion Good manufacturing practices Blackwell Publishing Ltd A. Ahmed Quality Manager,

More information

Notice of Rulemaking Hearing

Notice of Rulemaking Hearing Department of State Division of Publications 312 Rosa L. Parks, 8th Floor SnodgrassfTN Tower Nashville, TN 37243 Phone: 615.741.2650 Fax: 615.741.5133 Email: register.information@tn.gov For Department

More information

A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products

A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products A Life Cycle Approach to Raw Material Qualification for Cell and Gene Therapy Products Angela Whatley, Ph.D. Office of Tissues and Advanced Therapies CBER/FDA CMC Strategy Forum on Cell & Gene Therapies

More information

Compounding Animal Drugs From Bulk Drug Substances; Draft Guidance for Industry;

Compounding Animal Drugs From Bulk Drug Substances; Draft Guidance for Industry; This document is scheduled to be published in the Federal Register on 05/19/2015 and available online at http://federalregister.gov/a/2015-11982, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN

More information

The Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach

The Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach The Emerging Role of Post-Market Evidence Generation in Decision-Making: Linkages to the Product Lifecycle Approach CADTH Symposium April 6, 2009 Maurica Maher, MD, MSc Associate Director Office of Legislative

More information

Regulation of Microbiota- Based Products

Regulation of Microbiota- Based Products Regulation of Microbiota- Based Products LCDR Matthew Steele, PhD Team Leader, Regulatory Review Branch 1 Division of Vaccines and Related Products Applications CBER/OVRR My presentation is an informal

More information

Laboratory: Document Type: Original Date Adopted: Previous Document: Transfusion Services Procedure 04/01/02 TRB-9 Revision 4

Laboratory: Document Type: Original Date Adopted: Previous Document: Transfusion Services Procedure 04/01/02 TRB-9 Revision 4 Laboratory: Document Type: Original Date Adopted: Previous Document: Transfusion Services Procedure 04/01/02 TRB-9 Revision 4 Document Author: Document Owner: Acknowledgement / Required Copy Holders*:

More information

Plasma for Fractionation

Plasma for Fractionation www.pei.de Plasma for Fractionation Regulatory & Quality Standards in the EU Dr. Sabine Wegehaupt Inspection Services for Biological Medicinal Products IPFA Workshop Stellenbosch December 01-02, 2015 Plasma

More information

Proficiency Testing Turning Pitfalls into Positive Outcomes

Proficiency Testing Turning Pitfalls into Positive Outcomes Proficiency Testing Turning Pitfalls into Positive Outcomes Presented by: Margaret Blaetz, CLC, MLT(AMT), CCCP(AAPOL) CEO/Technical Consultant East Coast Clinical Consultants, LLC National Manager of Laboratory

More information

Guidance for Industry Compounding Animal Drugs from Bulk Drug Substances

Guidance for Industry Compounding Animal Drugs from Bulk Drug Substances #230 Guidance for Industry Compounding Animal Drugs from Bulk Drug Substances DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this

More information

Implementing 7 Day Platelet Dating with the Platelet PGD Test

Implementing 7 Day Platelet Dating with the Platelet PGD Test Implementing 7 Day Platelet Dating with the Platelet PGD Test The Verax Biomedical Platelet Pan Genera Detection (PGD ) Test is a rapid, qualitative immunoassay for the detection of aerobic and anaerobic

More information

BIOVIGILANCE IN THE UNITED STATES: Regulatory Perspective

BIOVIGILANCE IN THE UNITED STATES: Regulatory Perspective BIOVIGILANCE IN THE UNITED STATES: Regulatory Perspective Alan E. Williams, Ph.D. Office of Blood Research and Review Center for Biologics Evaluation and Research US Food and Drug Administration 15th International

More information

Starting from Scratch: Experiences with a Focused Apheresis Service

Starting from Scratch: Experiences with a Focused Apheresis Service Starting from Scratch: Experiences with a Focused Apheresis Service University of Virginia Tamila Kindwall-Keller, DO, MS September 21, 2018 Disclosures Medical Monitor for BMT CTN 1301 Back Up Medical

More information

Structure and Mandate of FDA

Structure and Mandate of FDA Structure and Mandate of FDA Leonard Sacks, M.D. Office of Medical Policy Center for Drug Evaluation and Research FDA FDA Clinical Investigator Training Course November 13, 2018 Mission of regulatory agencies

More information